Esophageal adenocarcinoma (EA) is characterized by a poor prognosis making the identification of clinically targetable proteins essential for improving patient outcome. We report the involvement of multiple alterations of the MET pathway in EA development and progression. Microarray analysis of Barrett's metaplasia, dysplasia, and EA revealed overexpression of the MET oncogene in EAs but only those with MET gene amplification. STSamplification mapping revealed that the boundary of the MET amplicon in these EAs is defined by fragile site FRA7G. We also identified an amplicon at 11p13 that resulted in amplification and overexpression of CD44, a gene involved in MET autophosphorylation upon HGF stimulation. Tissue microarrays with phospho-METspecific antibodies demonstrated a uniformly high abundance of MET activation in primary EA and cells metastatic to lymph nodes but to a lesser extent in a subset of metaplastic and dysplastic Barrett's samples. Increased expression of multiple genes in the MET pathway associated with invasive growth, for example, many MMPs and osteopontin, also was found in EAs. Treatment of EA-derived cell lines with geldanamycin, an inhibitor for tyrosine kinases including MET receptor kinase, reduced cell migration and induced EA cell apoptosis. The data indicate that upregulation of the MET pathway may contribute to the poor outcome of EA patients and that therapeutic agents targeting this pathway may help improve patient survival.
Introduction
Esophageal adenocarcinoma (EA) is the most rapidly increasing cancer in the Western countries and the prognosis for these patients remains extremely poor, with 5-year survival rates of B10% (Farrow and Vaughan, 1996; Devesa et al., 1998) . EA arises from Barrett's esophagus, a columnar metaplastic epithelium that replaces the normal squamous epithelium of the lower esophagus as a result of chronic gastroesophageal reflux. Oncogenic progression through a metaplasiadysplasia-carcinoma sequence has been observed and is accompanied by myriad genetic alterations, including mutations in oncogenes and tumor suppressor genes, aneuploidy, and gene amplification (Barrett et al., 1999) . The CDKN2A and TP53 tumor suppressor genes may be inactivated by DNA methylation or mutations, often in conjunction with loss of heterozygosity (LOH) at the genes' loci that was observed early in EA development (Blount et al., 1993; Gonzalez et al., 1997; Wong et al., 1997) . We have identified novel genomic amplification, which may result in overexpression of genes playing an important role in EA tumorigenesis, in chromosomes 8p22-23, 19q12, 14q13, 12q14 in a series of EAs and reported that the combined gene amplification events occur in >50% of all tumors examined (Hughes et al., 1998; Lin et al., 2000b Lin et al., , 2002 Miller et al., 2003a, b) .
The MET gene, a receptor tyrosine kinase (RTK), was initially identified as an oncogene in osteosarcoma resulting from the fusion of the TPR sequence and the intracellular domain of MET (Cooper et al., 1984) . Under physiological circumstances, activation of MET occurs by binding of the ligand, hepatocyte growth factor (HGF), to the extracellular domain of MET thus stimulating phosphorylation of Y1234/1235 and activating MET's autocatalytic domain (Ferracini et al., 1991; Naldini et al., 1991) . MET carboxy-terminal binding domain (Y1349/1356) is subsequently autophosphorylated and might stimulate many downstream genes in the MET pathways, including members of the matrix metalloproteases (MMP) family, osteopontin (OPN), plasminogen activator (uPA), and integrins, all associated with an invasive growth phenotype (Trusolino and Comoglio, 2002; Zhang and Vande Woude, 2003) . Mechanisms for oncogenic activation of MET and/or MET pathways in cancers appear multifaceted. HGF concentrations in tissues are normally regulated by HGF-secreting mesenchymal cells and cancer cells can often subvert the normal ligand-mediated control of MET activation. Oncogenic activation of the MET gene through gene amplification and overexpression represents another mechanism in many human cancers (Trusolino and Comoglio, 2002) . Both germline and somatic mutations resulting in activation of MET are also observed in cancers (Jeffers et al., 1997; Trusolino and Comoglio, 2002) . Activation of MET via autocrine or paracrine mechanisms may also lead to tumorigenesis and metastasis (Trusolino and Comoglio, 2002) . The TPR-MET fusion products resulting from chromosomal rearrangement may cause oncogenic transformation (Rodrigues and Park, 1993; Peschard et al., 2001) .
In the present study, we demonstrated that the highest MET mRNA expression in EAs was a consequence of MET gene amplification. The fragile site FRA7G defined the boundaries of the MET amplicon in the primary EAs. In addition, we identified an amplicon at 11p13 resulting in CD44 amplification and overexpression. Microarrays revealed that many genes in the MET signaling network, associated with cell migration and invasive growth, were upregulated during EA development and progression. HGF treatment of MET-expressing EA cell lines induced or increased expression of several MMP genes. Geldanamycin, a clinically used therapeutic tyrosine kinase inhibitor, reduced MET expression, inhibited cell migration, and induced EA cell apoptosis. Our data provide evidence for a prominent role of the MET pathways in the development and dissemination of EA and possibility of therapeutic targeting of this pathway in helping survival of EA patients.
Results
Increased MET mRNA expression results from gene amplification Affymetrix U133A arrays were utilized to analyse MET oncogene expression in randomly selected nine samples of Barrett's metaplasia, seven metaplastic/low-grade dysplasia, eight low-grade dysplasia, seven high-grade dysplasia, and 15 EAs. Two tumors demonstrated >10-fold increased expression of MET mRNA relative to all remaining tumors and Barrett's samples (Figure 1a) . We speculated that highly upregulated MET transcription might result from gene amplification. We analysed DNA from 75 EAs, which included 13 of 15 EAs examined in U133A arrays, with their corresponding normal samples and four EA cell lines using multiplex quantitative genomic-PCR (QG-PCR) (Figure 1b ). Six out of 75 (8%) primary tumors, including the two EAs (B18 and K89) that showed increased mRNA levels in the microarrays, demonstrated increased gene dosage of MET (the ratio of Tumor MET/GAPDH : Normal MET/ GAPDH X2.0; Figure 1a and b). MET amplification was not detected in dysplastic Barrett's mucosa adjacent to the two MET-amplified EAs (B18 and K89) or any of the 22 microdissected cases of high-grade dysplasia samples (data not shown).
Using a similar mRNA to DNA reverse strategy to analyse amplification of genes related to MET pathways, we found that CD44, a MET-activating transmembrane glycoprotein, showed very high level of gene expression (>15-fold) in one tumor (Figure 1c) . QG-PCR analysis using DNA from 36 (randomly selected from the 75 sample pool) paired normal and EA samples confirmed CD44 gene amplification but only in the tumor showing high mRNA overexpression (Figure 1d ). This is, however, a novel amplicon in EA at 11p13. mRNA expression of PLAU (uPA, plasminogen activator) gene of the MET pathways was increased >36-fold in one tumor; however, uPA amplification was not detected in this tumor or in the other 48 EAs (randomly selected from the 75 EA sample pool) examined ( Figure  1e and f). The levels of HGF mRNA in U133A arrays were nearly unchanged in all metaplastic, dysplastic, and malignant tissues.
Fragile site FRA7G sets the boundaries of the MET amplicon The MET proto-oncogene lies within the chromosome band 7q31.2 where the fragile site FRA7G is also localized. We hypothesized that breakage at the fragile site FRA7G may define the boundaries of the MET amplicon based on the evidence from the breakagefusion-bridge (BFB) cycle model (Coquelle et al., 1997; Hellman et al., 2002) . The six tumors containing the MET amplicon ( Figure 1b) were analysed for changes of DNA copy number using QG-PCR with 19 STS markers spanning >30 Mb but intensively localized within the fragile site FRA7G region (Figure 2a) . The mean values shown on the Y-axis represent the ratio of T(sample/GAPDH):N(sample/GAPDH) calculated from three or more replicate QG-PCR reactions using GAPDH as an internal control. An evident decline in DNA dosage for all six tumors is detected at the borders of FRA7G (markers D7S18 and D7S1650) (Figure 2a and b). The center of amplicon is near the MET oncogene and confined within the FRA7G fragile site (Figure 2b ), indicating that FRA7G breakage may set the boundaries of the MET amplicon and may be involved in initiating or promoting BFB cycles during MET amplification events. MET is also amplified in OE33 cell line; however, a large amplified unit (>30 Mb) was detected across the 7q arm beyond both telomeric and centromeric boundaries of the FRA7G. Therefore FISH technology could not define the relationship of the MET amplicon and FRA7G in this cell line.
Activation of the MET RTK is observed both in Barrett's metaplasia and EA To further investigate the MET signaling pathway in the development and metastatic potential of EA, we examined nondysplastic, dysplastic Barrett's mucosa, and EAs at the protein level using immunohistochemistry (IHC) with tissue microarrays (TMA). MET protein expression could be observed in metaplastic (8/ 9) and dysplastic Barrett's (11/11) Treatment with HGF and geldanamycin in EA cell lines Detection of MET activation in primary EA led us to investigate the sensitivity of cultured EA cells to geldanamycin, a compound that has been used in clinical trails and inhibits many tyrosine kinases including MET receptor. Whole-cell lysates (WCL) and MET immunoprecipitates (IP) from serum-starved Bic-1 cells treated with HGF were blotted and hybridized with MET and antiphosphotyrosine (pTyr) antibodies. Bic-1 cells showed an increase in phosphorylation of MET after HGF treatment (Figure 3a) , which is consistent with the data shown in Figure 2f and with previous studies from others (Ferracini et al., 1991; Naldini et al., 1991) . Treatment of the EA cell lines with increasing concentrations of geldanamycin caused a reduction in MET protein levels (Figure 3b) . Three EA cell lines demonstrated reduced cell viability with increasing concentrations (0-500 nM) of geldanamycin treatment as determined using MTT assays (Figure 4a ). Geldanamycin caused cytostasis leading to cell apoptosis but not cytotoxicity as shown by cell nuclear condensation and DNA fragmentation laddering (Figure 4b and c) . Although the involvement of other HSP90-dependent molecules cannot be excluded for the sensitivity of Seg-1, Flo-1, and Bic-1 cells to geldanamycin treatment (Figure 4a-c) , our data clearly demonstrate that geldanamycin can directly reduce MET protein expression ( Figure 3b ) and directly inhibit HGF-induced tumor cell migration (Figure 4d) . Alternatively, the reduced sensitivity of OE33 cells to geldanamycin treatment may reflect the high-level MET gene amplification in these cells (Figure 4a ).
One attribute of MET pathway activation is the ability to induce cellular migration. EA cell line Flo-1, which exhibits MET protein expression but not activation (phospho-MET negative; Figure 2f ), is slow growing but highly mobile. These cells were selected for their ability to repopulate a wounded cellular area on a culture dish. Cells grown in media with HGF present were able to migrate and repopulate the wound after 24 h (Figure 4d ). In cells grown in the presence of both HGF and geldanamycin, however, migration into the wound was almost entirely abrogated (Figure 4d ). Taken together, geldanamycin can inhibit cancer cell migration and induce malignant cell apoptosis.
Upregulation of genes associated with MET pathways Activation of MET is known to convey multiple downstream signaling cascades. We were particularly interested in the genes directly relevant to invasive growth phenotype of the MET signaling network, for instance, those contributing to extracellular matrix (ECM) remodeling and cell migration. We investigated expression levels of these genes using both U133A arrays and IHC in primary tissue specimens. At the mRNA level, multiple members of MMP gene family (Figure 5a ), secreted proteins osteopontin (OPN) and osteonectin (SPARC) (Figure 5b ), integrin beta-like 1 (ITGBL1) (Figure 5c ), and PLAUR (uPA urokinase receptor) (Figure 5d ) were found upregulated in a subset of EAs. Integrins ITGA5, ITGAM, and ITGB2 also were overexpressed in a subset of EAs (data not shown). MMP-3, MMP-9, MMP-11, MMP-12, OPN, and ITGBL1 were expressed primarily or exclusively in malignant tissues (Figure 5a-c) .
To validate the mRNA data from microarray analysis, we performed RT-PCR on a small subset of primary EAs using primers crossing introns of MMP-1, MMP-3, MMP-7, OPN, and several other genes (Figure 6a) . The results were consistent with the array studies. In addition, the products of some of these genes were validated at the protein level using IHC (Figure 6b ). MMP-1 was expressed in both Barrett's mucosa and EA tissue sections (Figure 6b) . Expression of MMP-3 was also observed both in Barrett's and EA samples (Figure 6b) . Expression of MMP-9 and MMP-13 was not observed in either the Barrett's or EA cells, but rather in stromal cell elements (Figure 6b ). Consistent with microarrays and RT-PCR results ( Figures  5b and 6a) , OPN was only observed in EA tissues (not shown).
HGF-induced expression of MMP-1, -2, and -3 To analyse whether any of the genes expressed in primary EA tissues were HGF inducible in EA-derived cells, Bic-1 cells were treated with 50 ng/ml HGF for 4, 6, 8, and 24 h postserum starvation and evaluated for transcriptional regulation of MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MET, and OPN using RT-PCR ( Figure 6c ). GAPDH expression served as the sample control and was unaffected by the HGF treatment (Figure 6c ). Transcriptional upregulation under HGF treatment was observed for the MET, MMP-1, MMP-2, and MMP-3 genes, especially at 8 h (Figure 6c ), but not for MMP-7, MMP-9, and OPN expression (data not shown).
Discussion
In cancer, oncogenic activation of MET can occur by gene amplification and overexpression independent of binding to its ligand HGF (Trusolino and Comoglio, 2002) . In this report, we identified 8% (6/75) of EAs as having amplified and overexpressed MET. The MET oncogene is known to lie within the locus containing the common fragile site, FRA7G (Huang et al., 1998) . Common fragile sites are regions in the genome that are peculiar, prone to breakage following replication stress (Arlt et al., 2003) , and are frequently associated with chromosomal deletions or rearrangements in tumor cells (Matsuyama et al., 2003) . Breakage at FRA7G and other fragile sites has previously been implicated in triggering BFB cycles and driving amplification of selected genes in cultured hamster cells (Coquelle et al., 1997) and in tumor cell lines, including MET amplification in a gastric cancer cell line (Ciullo et al., Figure 4 Geldanamycin induces cellular apoptosis and inhibits wound repopulation. (a) Dose-response curves of Seg-1, Flo-1, Bic-1, and OE33 EA cell lines to geldanamycin. Cells were treated for 72 h and cell viability assessed using the MTT assay. Graphs represent the percentage of viable cells as compared to control cells at each concentration. Three cell lines demonstrated a marked decrease in cell viability between 0 and 100 nM concentrations of geldanamycin, and MET-amplified OE33 cells showed the least sensitivity. (b) DAPIstained cells were examined for nuclear morphology following treatment with 100 and 500 nM geldanamycin. Seg-1, Bic-1, and Flo-1 cells exhibited nuclear condensation indicative of cells undergoing apoptosis. (c) DNA fragmentation was observed in the Seg-1 and Flo-1 cell lines. (d) Cell wounding was performed using confluent layers of EA cell lines. Flo-1 cells were able to migrate and repopulate the wound after 24 h in the presence of HGF. Wound repopulation was blocked nearly completely with 100 nM geldanamycin even in the presence of HGF. Figure 5 Expression of mRNA corresponding to genes related to the invasive growth phenotype of the MET pathways in esophageal tissues determined using Affymetrix U133A arrays. (a) Elevated MMP-1 and MMP-7 mRNA levels were found in Barrett's metaplasia, dysplasia, and EA, while elevated MMP-3, MMP-9, MMP-11, and MMP-12 mRNA levels were found primarily in highgrade dysplasia and EAs. (b) Increased expression of osteopontin (OPN) and osteonectin (SPARC) was also primarily observed in EAs, as were integrins, shown here is integrin beta-like 1 (ITGBL1) (c), and the plasminogen activator receptor uPAR (d).
2002; Hellman et al., 2002) . Our findings, in which the boundaries of MET amplicon in all six primary EAs mapped within FRA7G, are consistent with this proposed mechanism and are the first such example in primary tumors.
The importance of the MET gene in many tumor types prompted us to investigate whether other genes of the MET pathways may also be targets for genomic alterations. Identification of outlier-type overexpression pattern for CD44 in EA supported this notion. CD44 has been reported as a potential candidate gene of chromosome 11p13 amplification in cultured gastric cancer cell lines (Fukuda et al., 2000) . CD44 has been shown to play an integral role as a binding partner and signal transducer of MET protein signaling (OrianRousseau et al., 2002) . Alternative transcripts, most notably CD44v6, have been identified as being upregulated after cellular stimulation with HGF (Recio and Merlino, 2003) . Mice lacking functional CD44 showed aborted metastasis formation although the tumor incidence remained unchanged (Weber et al., 2002) . Indeed, we have found that the EA with amplified and overexpressed CD44 is uniformly positive for staining with both anti-pMET Y1234/5 and anti-pMET Y13409, indicating the activation of MET in this tumor.
Because many genes (targets or agonists) of the MET pathways function in ECM remodeling, cell motility, and invasive growth, elevated activities of these genes found in EAs may account for the early metastasis and extremely poor prognosis of EA patients. SPARC (osteonectin) has been associated with tumor cell motility and invasion in a variety of tumors (Briggs et al., 2002) . Biochemical studies show that peptides from proteolysis of SPARC by MMP-3 regulate endothelial cell proliferation and/or migration and can dose-dependently promote angiogenesis (Sage et al., 2003) . Increased expression of four integrin members (ITGBL1, ITGAM, ITGB2, and ITGA5) was found in EAs. Integrins, a group of cell adhesion receptors, are known to interact with RTKs including MET and may be directly or indirectly involved with uPA, MMPs, and OPN to influence tumor cell invasion and endothelial cell proliferation (Eliceiri, 2001; Weber, 2001; Hynes, 2002; Guo and Giancotti, 2004) . Both uPA and its receptor uPAR were overexpressed in a subset of EAs. uPA is activated upon binding uPAR, and converts plasminogen to plasmin. Plasmin activates pro-MMPs and may directly induce ECM degradation during tumor invasion (Guo and Giancotti, 2004) . We found that several matrix metalloproteinases (MMPs) showed mRNA overexpression in both EA and high-grade dysplastic Barrett's tissues and demonstrated that HGF-treated EA cells can directly induce the expression of a subset of MMPs. OPN also plays important roles in cancer dissemination through complex associations and interactions in the MET pathways (Weber, 2001 ), and we found that OPN was primarily expressed in EAs although it was not directly inducible by HGF treatment.
Currently, no specific therapy is in use targeting known genetic alterations involved in the development of EA. Geldanamycin, a benzoquinone ansamycin antibiotic, downregulates HGF-MET signaling by binding heat-shock protein-90 (Hsp90) and destabilizing Hsp90's client oncoproteins including MET (Stebbins et al., 1997; Blagosklonny, 2002) . Of most relevance to cancer, geldanamycin has been shown to be an inducer of cellular apoptosis in malignant cells (Stebbins et al., 1997; Blagosklonny, 2002) . The mechanistic basis for this role is primarily attributable to its potent inhibition of the abundant and ubiquitous cellular chaperone Hsp90. Interestingly, EA cell line OE33 containing highly amplified MET was the least sensitive to the treatment of geldanamycin, indicating that a high abundance of the MET transcript resulting from gene amplification may bypass geldanamycin-induced malignant cell apoptosis. Alternatively, the sensitivity to geldanamycin in other esophageal tumor cell lines may also be due to inhibition of additional HSP90-dependent molecules, which were not characterized as part of this study.
RTKs serve as the essential link between the extracellular milieu and intracellular signaling machinery, and aberrations of RTKs may often lead to developmental abnormalities, metabolic defects, or oncogenesis (Trusolino and Comoglio, 2002 ). In the current communication, we found a uniformly high level of phospho-MET staining, indicating MET activation, in EAs and a lesser staining in a subset of metaplastic and dysplastic tissues. The findings implicate a possibility for pre-emptive disease management strategies should MET-specific therapies become available. Recently, several groups have reported modest success in developing novel therapeutic strategies for targeting the MET receptor in vivo, including adenoviral-delivered ribozymes, MET decoys, small molecular inhibitors, and anti-MET antibodies (Cao et al., 2001; Christensen et al., 2003; Kim et al., 2003; Kong-Beltran et al., 2004; Michieli et al., 2004; Zhang et al., 2004) . Indeed, we found that MET pathway activation is prominent in EA, and geldanamycin reduces EA cell migration and induces EA cell apoptosis. Thus, anti-MET-targeted therapies may prove efficacious for patients with EA.
Materials and methods
Tissue procurement, cell lines, and reagents Patient consent was received according to the guidelines of the University of Michigan institutional review board (IRB). Tissues were collected from patients undergoing esophagectomy at the University of Michigan Health System between 1991 and 2001, and none of patients received preoperative radiation or chemotherapy. Specimens were frozen in liquid nitrogen and stored at À801C. Cryostat sections, embedded in OCT compound (Miles Scientific, Naperville, IL, USA), of all samples were analysed and only a portion of tumors containing >70% tumor cellularity were utilized. DNA was isolated from EA and matched normal surrounding mucosa. DNA and RNA samples and tissue sections used in all assays were randomly selected from our sample pools based upon the tumor sample availability. Frozen sections (10 mm) were used for microdissection and DNA extraction from high-grade dysplastic Barrett's tissues. The Seg-1, Flo-1, and Bic-1 cell lines were derived from human EAs as previously described (Hughes et al., 1997) . The OE33 EA cell line is amplified at the MET locus (Rosenberg et al., 2002) . Cell lines were grown in 100 mm dishes with DMEM containing 10% fetal bovine serum and 100 U/ml penicillin G and 100 mg/ml streptomycin sulfate antibiotics at 371C in a 5% CO 2 humidified atmosphere.
Immunohistochemistry
Tumor diagnoses and construction of TMA blocks were performed as previously described (Kononen et al., 1998) . Briefly, TMA was made from 64 EAs, eight lymph node metastases and eight dysplastic and 11 nondysplastic Barrett's mucosa sections from 59 patients, in addition to 10 normal controls from various tissues. Antigen retrieval was performed using microwave pretreatment for 15 min in 0.01 M citrate buffer (pH 6.0). The slides were then blocked with 5% normal goat serum in PBS for 20 min, and endogenous peroxidase activity was quenched with 0.5% hydrogen peroxide in PBS. Sections were then incubated with Phospho-MET Y1349 (#3121, Cell Signaling Technology Inc., Beverly, MA, USA), Phospho-MET Y1234 (#3126, Cell Signaling Technology), or c-MET (#sc-10, Santa Cruz Biotechnology, Santa Cruz, CA, USA), OPN (#sc-1059, Santa Cruz Biotechnology) or MMPs (MMP1, #RDI-MMP1abm-E5 and MMP13, #RDI-MMP13abm, Research Diagnostics Inc., Flanders, NJ, USA; MMP3, #5980-0280, Biogenesis Inc., Kinston, NH, USA; MMP9, #sc-6840, Santa Cruz Biotechnology) antibodies overnight at 41C.
Affymetrix microarrays and RT-PCR
Isolation of RNA for Affymetrix oligonucleotide arrays U133A and data normalization have been described previously (Lin et al., 2004) . Total RNA for quantitative RT-PCR was isolated using the Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA). For evaluation of MMP expression following treatment with human recombinant HGF (Cell Sciences, Norwood, MA, USA) in EA cells, RNA was isolated and 2 mg of DNase I pretreated total RNA was reverse transcribed as previously described (Lin et al., 2000a) . A 1 ml portion of each reaction product underwent RT-PCR with GAPDH as an internal control. The RT-PCR primers were designed to crossing at least one intron and are available upon request.
Quantitative genomic-PCR DNA isolation and preparation were carried out and fine mapping of candidate genes for known amplified regions was carried out using QG-PCR as previously described (Lin et al., 2000a) . In brief, forward primers were end-labeled with [g-32 P]ATP (NEN Life Science Products, Boston, MA, USA) with T4 polynucleotide kinase (New England Biolabs, Beverly, MA, USA). PCR was performed using Taq polymerase (Promega), and the PCR products were resolved on 8% denaturing polyacrylamide gels. PCR product signal ratios (Ts/c:Ns/c) for both the tumor (Ts/c, tumor tested fragment/ tumor GAPDH fragment) and normal DNA samples (Ns/c, normal tested fragment/normal GAPDH fragment) were quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). Amplification ratios X2.0 were considered indicative of DNA amplification. All experiments were performed in triplicate.
Western blotting and immunoprecipitation
Western blots were performed as previously described (Lin et al., 2004) . The same antibodies used for IHC were used in Western blot analyses. For immunoprecipitation assays, cell lines were grown to 70% confluence and serum starved for 12-16 h prior to treatment with human recombinant HGF (Cell Sciences). Cells were treated with HGF (50 ng/ml) for 7.5 min and harvested in cell lysis buffer (0.5% NP-40, 25 mM Tris pH 7.5, 100 mM NaCl, and 50 mM NaF) containing Phosphatase Inhibitor Cocktail 2 (Sigma, St Louis, Missouri, MO, USA) and Protease Inhibitor Cocktail (Sigma). Cell lysates were precleared and the MET protein immunoprecipitated following incubation with c-MET antibody (sc-10, Santa Cruz) and protein A-Sepharose (Sigma) at 41C for 4 h. Beads were washed with YP-IP wash buffer (0.1% NP-40, 25 mM Tris pH 7.5, and 150 mM NaCl) and 1/100 phosphatase inhibitor 2 (Sigma). After membrane blotting, proteins were hybridized with anti-c-MET (#sc-10, Santa Cruz) or antiphosphotyrosine (#4G10, Upstate Biotechnology). Expression of b-actin or b-tubulin was determined with a 1:2000 dilution of anti-b-actin (ab6276, Abcam, Cambridge, UK) or antib-tubulin (T5293, Sigma) monoclonal antibodies and used as loading controls.
Apoptosis and cell wounding assays
For apoptosis assays, cell viability assays were conducted using the MTT reagent (ATCC, Manassas, VA, USA). Cell lines were treated with 0, 12.5, 25, 50, 100, 250, and 500 nM concentrations of geldanamycin (Sigma) for 72 h prior to exposure to MTT reagent and cell viability assessment. Cell morphology was assessed in Bic-1, Seg-1, and Flo-1 cells following 24 h treatment with geldanamycin at 500 nM and 1 mM concentrations. Cells were stained with DAPI (Vector Laboratories) and propridium iodide (Sigma) and visualized using a Zeiss Axioskop fluorescent microscope. For DNA fragmentation analysis, EA cell lines were treated with 200 nM, 500 nM, and 1 mM geldanamycin for 48 h. The cell lysate containing the fragmented DNA was then centrifuged at 11 000 g for 20 min. The supernatant was treated with RNase A (50 mg/ml) at 371C for an additional hour and DNA was extracted.
For cell wounding assay, cell lines were grown to confluence and serum starved (24 h) and wounded with a pipette tip before treatment with either HGF (50 ng/ml) or both HGF (50 ng/ml) and geldanamycin (100 nM). Cells were assayed for ability to repopulate the wound 24 h postwounding.
